Aktis Oncology

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO January 7, 2026 Aktis Oncology increases proposed IPO deal size by 50% to $300 million, adding a $100 million commitment from partner Eli Lilly The Boston, MA-based... Read more